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Pregnancy outcome in women with antiphospholipid 
syndrome on low-dose aspirin and heparin: a 
retrospective study
T. Naru,1 R.S. Khan 1 and R. Ali 1
ABSTRACT This retrospective review of hospital records analysed pregnancy outcome with 2 different treatments 
for women with recurrent miscarriage diagnosed with antiphospholipid syndrome in the index pregnancy. Of 
64 women, 29 had received aspirin and 35 aspirin plus heparin. Pregnancy-induced hypertension, prematurity, 
intrauterine growth restriction and neonatal death were considered as maternal and fetal complications. There 
were no significant differences in antenatal and maternal complications between the groups. However, there 
were significant differences in mean anticardiolipin IgG antibody levels. Aspirin alone or in combination with 
heparin was equally efficacious in women with antiphospholipid syndrome and recurrent miscarriage. 
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 ةسارد :نيرابيلهاو نيبرسلأا نم ةضفخنم ةعرجب نلجاعي تيلالا ديبلوفسوفلا تاداضم ةمزلاتمب تاباصلما ىدل لملحا جئاتن
ةيداعتسا
ليع تحمر ،ناخ ةقيدص لايزور ،روان ةرهاط
 عم صيخشتلا ثيدح طاقسإب تاباصلما لماوحلل ينتفلتمخ ينتلجاعم دعب لملحا جئاتن ليلحتل ىفشتسلما تلاجسل ةيداعتسا ةسارد هذه :ةـصلالخا
 يتلا تافعاضلما نم برتعا دقو .نيرابيلهاو نيبرسلأا نهنم 35 تقلت ،ةأرما 64 ةساردلا تلمش دقو .هيلإ راشلما لملحا في ديبلوفسوفلا تاداضم ةمزلاتم
 تافلاتخا كانه نكي لمو .ديلولا تومو ،محرلا لخاد ومنلا صقنو ،جادلخاو ،لملحاب ضرحلما مدلا طغض عافترا نم لك ةّنجلأاو تاهملأا بيصت
 ةيطسولا تايوتسلما في ًايئاصحإ ابه ُّدَتْعُي تافلاتخا كانه لباقلمابو .تاعومجلما ىدل لملحا ءانثأ وأ تاهملأا دنع تافعاضلما في ًايئاصحإ ابه ُّدَتْعُي
 ىدل ةيواستم )ةءافك( ةعاجن يذ نيرابيلها عم كراشتلاب وأ هدحول نيبرسلأا ءاطعإ ناك دقو .ينبيلويدراكلل يج ةيعانلما تانيتوبرلا نم تاداضملل
.ةرركتم تاطاقسإو ديبلوفسفلا تاداضم ةمزلاتمب تاباصلما
Issue de la grossesse de femmes présentant un syndrome des anticorps antiphospholipides traité par 
l’aspirine à faible dose et par l’héparine : une étude rétrospective
RÉSUMÉ Cette étude rétrospective des dossiers hospitaliers a analysé l’issue de la grossesse chez des femmes 
ayant fait des fausses couches à répétition, chez lesquelles un syndrome des anticorps antiphospholipides a 
été diagnostiqué et qui ont reçu deux traitements différents. Sur 64 femmes, 29 d’entre elles avaient reçu de 
l’aspirine, tandis que 35 étaient traitées avec de l’aspirine et de l’héparine. L’hypertension induite par la grossesse, 
la prématurité, les retards de croissance intra-utérine et les décès néonatals ont été considérés comme des 
complications maternelles et fœtales. Aucune différence significative en termes de complications prénatales et 
maternelles n’a été constatée entre les deux groupes. Cependant, des différences importantes ont été observées 
dans les taux moyens d’anticorps anticardiolipine IgG. L’aspirine seule possède la même efficacité que l’aspirine 
associée à l’héparine chez les femmes présentant un syndrome des anticorps antiphospholipides et ayant fait des 
fausses couches à répétition.




Antiphospholipid antibody syndrome 
(APS) is a disorder characterized by 
the presence of medium to high lev-
els of lupus anticoagulant antibodies 
(LAC) and anticardiolipin antibodies 
(aCL)—the so-called antiphospholi-
pid  antibodies  (aPL).  APS  was  first 
described in the early 1980s in patients 
with systemic lupus erythematosus 
[1,2] and is termed primary APS when 
it occurs in otherwise healthy people 
[3]. APS is associated with arterial and 
venous thrombosis and both early preg-
nancy loss and fetal death in advanced 
pregnancy [1–4]. While placental 
thrombosis and infarction are common 
findings in aPL-related intrauterine fetal 
deaths [4], thrombosis is not a universal 
finding and alternative mechanisms of 
pregnancy loss have been sought [5,6]. 
Prospective clinical studies have 
confirmed  that aPL are  risk  factors  for 
pregnancy loss, both in patients with 
systemic lupus erythematosus [5] and 
in healthy nulliparous women [7]. In 
women with a history of 3 or more con-
secutive pregnancy losses persistently 
positive tests for aPL were found in up to 
15%, and in these cases, subsequent fetal 
loss rates of up to 60%–90% were noted 
without  specific  treatment  [8,9]. aPL 
are also associated with a high incidence 
of pre-eclampsia, intrauterine growth 
restriction (IUGR), fetal distress and 
premature delivery [10,11].
A number of studies have evaluated 
the efficacy of treatment with low-dose 
aspirin, prednisolone, unfractionated 
low-molecular weight heparin and most 
recently intravenous gammaglobulin, 
either alone or in various combinations. 
However,  the findings have not been 
consistent [12,13]. Low-dose aspirin in 
combination with heparin was demon-
strated in 2 randomized controlled trials 
to lead to a significant improvement in 
the live birth rate [14,15].
This study aimed to determine the 
pregnancy outcome in women with 
APS and recurrent pregnancy loss who 
were treated with aspirin alone or aspi-
rin in combination with heparin during 
the index pregnancy. 
Methods
Sample and setting 
This study was conducted at the Aga 
Khan University Hospital in Karachi, 
Pakistan, a tertiary care unit with an 
average of 3500 deliveries per year. A 
dedicated outpatient service caters to 
high-risk obstetric care, early pregnancy 
complications and investigations in-
cluding Doppler ultrasound facilities in 
the fetomaternal unit. The nursing staff 
provides regular antenatal sessions as 
well as patient education and training 
for self-administered injections. 
The criteria for entry to the study 
were women who  suffered 2 or more 
1st or 2nd  trimester  fetal deaths or  at 
least 1 intrauterine death or neonatal 






The study was a retrospective analysis 
of women who voluntarily chose differ-
ent  treatments. From January 1994  to 
December 2003 the data were retrieved 
from a data indexing and coding system 
based on the International classification 
of diseases,  9th  edition. Of 84 women 
identified,  20  were  excluded  due  to 
incomplete documentation and the 
remaining 64 women were divided into 
2 groups: group A (n = 29) had received 
low-dose  aspirin  (75 mg  once  daily 
orally) while group B (n = 35) had re-
ceived aspirin (75 mg once daily orally) 
plus heparin (5000 IU subcutaneously 
twice daily) (group B) during the in-
dex pregnancy. The group of patient 
on aspirin treatment alone were those 
who had refused heparin, as injections 
were not acceptable to them. Aspirin 
had been commenced from the start 
of the pregnancy either after a positive 
pregnancy test or presence of cardiac 
activity on ultrasound scan until the 
34th week of gestation, while  in group 
B heparin had been started  in  the 2nd 
trimester and continued until the 36th 
week of gestation.
Most of the women were assessed 
before pregnancy when they came to 
the clinic for counselling regarding more 
than 2 pregnancy  losses  (intrauterine 
and/or neonatal deaths). Women were 
monitored fortnightly during the 1st tri-
mester for hypertension and thrombo-
cytopenia. Fetal monitoring was started 
from 24–26 weeks with monthly growth 
scans until delivery. Two-weekly scans 
were performed if severe early onset of 
IUGR was suspected along with umbili-
cal artery Doppler studies. The timing 
of delivery was assessed individually on 
the basis of current and past obstetric 
history and the onset of complications, 
e.g. pre-eclampsia, IUGR or abnormal 
Doppler results. Women whose preg-
nancy  reached  37  completed  weeks 
gestation were either induced or deliv-
ered by elective caesarean section. In 
women who received heparin during 
pregnancy, the treatment was used until 




The data were analysed using SPSS, 
version 10.  Independent sample  t-tests 
were used to compare 1st, 2nd and 3rd 
trimester pregnancy losses, neonatal 
deaths and status of aPL. Chi-squared 
and Fisher exact tests were used for 
the association between maternal age, 
gestational age, birth weight, status of 
aPL and pregnancy outcome. A P-value 
< 0.05 was considered significant. 
Results
A  total  of  64  women with  APS  and 
recurrent miscarriage were included in 
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group B received low-dose aspirin plus 
heparin. Tables 1 and 2 show the demo-
graphic details and antiphospholipid 
antibody status of the women. There 
were no significant differences between 
the groups with respect to maternal age, 
number of previous 1st,  2nd and 3rd 
trimester pregnancy losses and neonatal 
deaths.
There was a significant difference in 
the mean concentrations of aCL IgG 
titres between group A and group B 
[8.88 (SD 7.17) GPL versus 15.88 (SD 
13.77) GPL]  (P = 0.016)  (Table 2). 
The mean concentrations of aCL IgM 




There  were  no  significant  differ-






The mean gestational age and the 
neonatal birth weight were not  signifi-
cantly different between the groups; 
the mean gestational ages at delivery 
in groups A and B were 35.9 (SD 4.1) 
months and 35.6 (SD 3.6) months re-





baby in group A died due to congenital 
heart disease (Table 3). None of the 
women developed a thromboembolic 
or cerebrovascular event. 
Discussion 
APS is widely recognized as a risk factor 
for numerous obstetric complications, 
including recurrent miscarriage, IUGR, 
pre-eclampsia, fetal death and preterm 
labour. Since its original description, 
APS has emerged as the most impor-
tant treatable cause of recurrent mis-
carriage [2]. The prevalence of aPL in 
recurrent miscarriage is approximately 
15.5%  [9,16]. The risk of subsequent 
pregnancy loss in women with aPL and 
previous pregnancy loss is unknown but 
probably exceeds 60% [10]. 
A variety of treatment regimens 
have been used, both single agents and 
combinations, to improve the poor live 
birth rates among these women, with 
live births  reported  from 30% to 100% 
of pregnancies [1]. However, treatment 
of pregnant aPL-positive women to 
improve pregnancy outcome remains 
completely empirical. The paucity of 
data from large well-designed trials of 
different management options in com-
parable groups of pregnant women with 
this complex disease contributes to the 
difficulty in formulating recommenda-
tions for managing these pregnancies. 
The approach is guided by observa-
tional studies, personal knowledge and 
the opinions of others experienced in 
the management of such women.
Our study investigated women with 
APS in the index pregnancy treated 
with either aspirin alone or aspirin and 
heparin together. Analysis of the data 
did not reveal any statistically significant 
difference between the treatment groups 
in terms of live birth rate or the antenatal 




fered IUGR in groups A and B respec-
tively. Similarly, severe pre-eclampsia 
was observed  in 20.7% and 28.6% of 
Table 1 Age and pregnanacy characteristics of women treated with aspirin or aspirin plus heparin (n = 64)
Characteristic Group A Group B P-value
Aspirin (n = 29) Aspirin + heparin (n = 35)
Mean (SD) Mean (SD)
Maternal age (years) 28.8 (5.3) 29.6 (5.2) 0.575
1st and 2nd trimester pregnancy loss (No.) 2.28 (1.13) 2.43 (2.10) 0.726
3rd trimester pregnancy loss (No.) 0.21 (0.41) 0.34 (0.39) 0.300
Neonatal death (No.) 0.28 (0.53) 0.20 (0.47) 0.547
SD = standard deviation.
Table 2 Antiphospholipid antibody levels of women treated with aspirin or aspirin plus heparin (n = 64)
Antibody levels Group A Group B P-value
Aspirin (n = 29) Aspirin + heparin (n = 35)
Mean (SD) Mean (SD)
Anticardiolipin IgG (GPL) 8.88 (7.17) 15.88 (13.77) 0.016
Cardiolipin IgM (MPL) 10.73 (7.19) 12.30 (7.61) 0.403
SD = standard deviation; GPL = IgG phospholipid units; MPL = IgM phospholipid units.
طسوتلما قشرل ةيحصلا ةلجلماشرع سداسلا دلجلما 
ثلاثلا ددعلا
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the women respectively. These results 
are comparable to international data 
[11,12,16,17]. 
Stone et al. analysed the outcome 
of pregnancies after introduction of a 
standard protocol in 33 patients with 
APS and achieved a live birth rate of 
91% in women with primary APS even 
in those with significant past pregnancy 
morbidity with or without thrombosis. 
The outcome in the index pregnancy 
was influenced the most by past preg-
nancy outcome [18]. Branch and Kha-
mashta pointed out that treatment of 
APS must be individualized and related 
to previous pregnancy complications 
[19]. 
A prospective study of aPL-positive 
pregnant women with at least 3 sponta-
neous consecutive miscarriages recorded 
44% of  live births in women assigned to 
low-dose aspirin alone and 80% for those 
treated with aspirin plus subcutaneous 
heparin twice daily [14]. A comparable 
trial also found aspirin alone inferior to 
aspirin plus heparin (42% versus 71% live 
births) [15]. In view of the heterogene-
ous definition of  aPL  in  the  literature, 
Kutteh excluded women with LAC [14], 
whereas in the study of Rai et al., 80% of 
the patients had LAC in the absence of 
aCL [15]. Meanwhile, Farquharson et al. 
found the birth rate to be similar in both 
groups (72% with aspirin alone compared 
with 78% when heparin was added to the 
regimen) [20]. The uncertainty as to 
whether heparin is always needed comes 
from this uncontrolled prospective study 
with 91% live births with low-dose aspirin 
alone in aPL-positive pregnant women, 
who had a minimum of 2  spontaneous 
abortions and a history of only 6%  live 
births [18]. Differences in the inclusion 
and exclusion criteria used in different 
studies are a major cause of such discord-
ant findings [21].
Our study suggests that the women 
with aPL and recurrent pregnancy loss 
can be treated effectively with low-dose 
aspirin alone. As this study did not in-
clude untreated controls, we cannot 
exclude the possibility that aspects of 
obstetric care other than the treatment 
per se influenced pregnancy outcome.
An  important finding  in  this  study 
was  the statistical  significant difference 
in the IgG values between the aspirin 
group  and the aspirin plus heparin 
group (P  = 0.016). The maternal  and 
fetal complications in the 2 groups were 
similar. We cannot exclude the pos-
sibility of a better outcome in the aspirin 
and heparin group due to the addition 
of heparin. The persistent presence of 
IgG and IgM aCL needs to be clini-
cally monitored during pregnancy for 
optimal outcome. This may have some 
implications for further study and coun-
selling of these women. 
As complications still occur and 
the exact pathogenetic mechanism of 
these events in APS remains unclear, 
further randomized trials are required 
to determine the optimum regime for 
the management of APS pregnancies. 
Among combination therapies, aspirin 
together with heparin is currently one 
of the best treatments offered, with the 
fewest adverse drug effects. The pos-
sibility of adverse effects with heparin 
therapy for a longer duration, and the 
cost implications for low resource areas 
needs consideration. 
Table 3 Maternal and fetal outcomes of index pregnancies of women treated with aspirin or aspirin plus heparin
Maternal and fetal outcome Group A Group B P-value
Aspirin (n = 29) Aspirin + heparin (n = 35)
Pre-eclampsia (No.) 6 10 0.568
Preterm deliverya (No.) 9 12 0.498
Small-for-gestational age baby (No.) 5 8 0.757
Gestational age [Mean (SD) weeks] 35.9 (4.2) 35.6 (3.6) 0.720
Birth weight [Mean (SD) g] 2.5 (0.9) 2.4 (0.8) 0.581
Neonatal death (No.)
 Yes 6b 3 0.152
 No 23 32
aAt 26–37 weeks.  
b1 baby had congenital heart disease. 
SD = standard deviation.
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